Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

What's better than a good thing? More of a good thing. Income investors can find plenty of "good things" in the market these ...

The pharmaceutical giant and blue-chip favorite for dividend-focused investors, Pfizer Inc. (NYSE:PFE) fell by 3.5% in a week despite a growth in the sales including Comirnaty, owing to the threat ...

The UK Chancellor’s messaging at Davos recalled former Taoiseach Enda Kenny’s efforts to extol the recovery of the Irish ...

The doctor beamed onto a health clinic video screen in October to convince the regional health board to ban public clinics in ...

We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...

As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

As part of his love-in with infrastructure, the Prime Minister is vowing to 'rip up the rules' and grant planning licences ...